The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer.
The anthrapyrazoles are DNA-binding anticancer agents with broad spectrum preclinical activity and reduced potential for free radical generation compared with doxorubicin. In early clinical trials, the dose-limiting toxicity has been leukopenia, other side effects being minor, and promising antitumor activity has been shown, especially in breast cancer. It remains to be confirmed that the anthrapyrazoles are less cardiotoxic than doxorubicin, but it is clear that these drugs are showing real promise, appear significantly less toxic than doxorubicin, and seem to represent a genuine therapeutic advance.
Judson
I R
IR
Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, England.
D000818:Animals; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005544:Forecasting; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; C055925:anthrapyrazole